Solid Biosciences Business Update and Financial Results

 Company ends 2023 with approximately $123.6 million in cash and investments. Combined with gross proceeds from $108.9 million private placement in January, Solid has anticipated cash runway into 2026 —

— FDA cleared IND and granted Fast Track Designation and Orphan Drug Designation for Duchenne muscular dystrophy (Duchenne) gene therapy candidate SGT-003 with patient dosing in Phase 1/2 trial expected Q2 2024 —

— Company entered into non-exclusive licensing agreement for use of its proprietary, muscle-targeted AAV-SLB101 capsid —

https://www.globenewswire.com/news-release/2024/03/13/2845337/0/en/Solid-Biosciences-Provides-Fourth-Quarter-and-Full-Year-2023-Business-Update-and-Financial-Results.html